Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 ATC-codes for prescription drugs used to identify individuals receiving triple treatment

From: Perceived stress as a risk factor for peptic ulcers: a register-based cohort study

Drug group Generic name ATC-code
Proton Pump Inhibitors Omeprazole A02BC01
Pantoprazole A02BC02
Lansoprazole A02BC03
Rabeprazole A02BC04
Ensomeprazole A02BC05
H2-receptor antagonists Cimetidine A02BA01
Ranitidine A02BA02
Famotidine A02BA03
Nizatidine A02BA04
Niperotidine A02BA05
Roxatidine A02BA06
Ranitidine Bismuth Citrate A02BA07
Lafutidine A02BA08
Macrolides Erythromycin J01FA01
Spiramycin J01FA02
Midecamycin J01FA03
Oleandomycin J01FA05
Roxithromycin J01FA06
Josamycin J01FA07
Troleandomycin J01FA08
Clarithromycin J01FA09
Azithromycin J01FA10
Miocamycin J01FA11
Rokitamycin J01FA12
Dirithromycin J01FA13
Flurithromycin J01FA14
Telithromycin J01FA15
Other Antibiotics Amoxicillin J01CA04
Metronidazole J01XD01
Metronidazole G01AF01
Metronidazole P01AB01
Metronidazole A01AB17
Metronidazole D06BX01
Tinidazole P01AB02
Tetracycline D06AA04
Tetracycline S01AA09
Tetracycline S02AA08
Tetracycline S03AA02
Tetracycline J01AA07
Tetracycline A01AB13
  1. To be classified as triple treatment, one drug from either the proton pump inhibitor (PPI) or H2-receptor antagonist group combined with one macrolide and one other antibiotic. Both antibiotics had to be redeemed on the same date, whereas the PPI or H2-receptor antagonist could be redeemed within 60 days preceding antibiotics. Individuals redeeming prescriptions for PPIs or H2-receptor antagonists combined with either amoxicillin and metronidazole or tetracycline and metronidazole were also classified as triple treated